Drug Profile
Nadofaragene firadenovec - FKD Therapies
Alternative Names: AAV-IFN-apha-2b-gene-therapy-FKD-Therapies; Adenovirus-Delivered Interferon Alpha-2b; Adstiladrin; FE-999326; Instiladrin; Nadofaragene firadenovec-vncg; Nadofaragene firadenovec/Syn3; rAd-IFNα; rAd-IFNα/Syn3; SCH-209702/SCH-721015; SCH-721015; SCH-721015/SCH-209702; TR-002Latest Information Update: 14 Mar 2024
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer Ferring Pharmaceuticals; FKD Therapies; Trizell; University of Pennsylvania
- Class Antineoplastics; IFNA2B gene therapies; Immunotherapies
- Mechanism of Action Gene transference; IFNA2B expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bladder cancer
- Phase III Malignant-mesothelioma
Most Recent Events
- 25 Jan 2024 Efficacy data from a phase II trial in Bladder cancer presented at the 2024 Genitourinary Cancers Symposium (ASCO-GeCS-2024)
- 29 Nov 2023 Updated efficacy data from a phase III LANDMARK trial in Bladder cancer released by Ferring Pharmaceuticals
- 12 Sep 2023 Launched for Bladder cancer (Late-stage disease, Second-line therapy or greater, In adults) in USA (Intravesicular)